Dashboard
Financial statements
BIIB

Company financials

Biogen

Health Care Biotechnology Cambridge, Massachusetts Last filing Feb 6, 2026 · FY2025
Revenue FY2025
$9.9B
Net income FY2025
$1.3B

Balance Sheet

Assets, liabilities, and equity

32 accounts · 5 years
Account 2025 2024 2023 2022 2021
Statement
BS Assets Cash $3.0B $2.4B $1.0B $3.4B $2.3B
BS Assets Short Term Invest $807.2M $179.7M $416.8M $1.5B $1.5B
BS Assets Accts Receivable $3.0M $1.4B $1.7B $1.7B $1.5B
BS Assets Inventory $2.2B $2.5B $2.5B $1.3B $1.4B
BS Assets Prepaid Expenses $1.1B $752.5M $1.2B $1.4B $740.8M
BS Assets Other Current Assets $1.1B $752.5M $1.2B $1.4B $740.8M
BS Assets Total Current $9.0B $7.5B $6.9B $9.8B $7.9B
BS Assets PPE $3.1B $3.2B $3.3B $3.3B $3.4B
BS Assets Op Lease ROU $265.4M $356.4M $420.0M $403.9M $375.4M
BS Assets Goodwill $6.5B $6.5B $6.2B $5.7B $5.8B
BS Assets Intangible Assets $9.2B $9.7B $8.4B $1.9B $2.2B
BS Assets Deferred Tax Assets $292.5M $324.2M $928.6M $1.2B $1.4B
BS Assets Other Noncurrent $750.6M $560.5M $745.0M $1.5B $1.9B
BS Assets Total $29.4B $28.0B $26.8B $24.6B $23.9B
BS Liab Accts Payable $432.0M $424.2M $403.3M $491.5M $589.2M
BS Liab Accrued Liab $0 $0 $117.5M $0 $0
BS Liab Current Debt $6.3B $1.7B $150.0M $0 $999.1M
BS Liab Other Current $2.8B $2.8B $2.6B $2.5B $2.5B
BS Liab Total Current $3.3B $5.5B $3.4B $3.3B $4.3B
BS Liab Long Term Debt $6.3B $6.3B $6.9B $6.3B $6.3B
BS Liab Op Lease Noncurrent $290.4M $334.5M $400.0M $333.0M $330.4M
BS Liab Deferred Tax Liab $507.6M $190.5M $641.8M $334.7M $694.5M
BS Liab Other Noncurrent $748.5M $732.3M $781.1M $944.2M $1.3B
BS Liab Total $11.2B $11.3B $12.0B $11.2B $12.9B
BS Equity Preferred Stock $0 $0 $0 $0 $0
BS Equity Common Stock $0 $100.0K $100.0K $100.0K $100.0K
BS Equity APIC $863.1M $569.4M $302.5M $73.3M $68.2M
BS Equity Retained Earnings $20.6B $19.3B $17.6B $16.5B $13.9B
BS Equity Treasury Stock $3.0B $3.0B $3.0B $3.0B $3.0B
BS Equity AOCI $-182.0M $-136.2M $-153.7M $-164.9M $-106.7M
BS Equity Total $18.3B $16.7B $14.8B $13.4B $10.9B
BS Equity Total Liab and Equity $29.4B $28.0B $26.8B $24.6B $23.9B